References
- Ahmed, S., Gasparyan, A. Y., Zimba, O. (2021). Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic. Rheumatol. Int., 41 (2), 243–256.
- Barbhaiya, M., Levine, J. M., Bykerk, V. P., Jannat-Khah, D., Mandl, L. A. (2021). Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City. Ann. Rheum. Dis., 80 (10), 1352–1354.
- Bartels, L. E., Ammitzb¸ll, C., Andersen, J. B., Vils, S. R., Mistegaard, C. E., Johannsen, A. D., Hermansen, M. F., Thomsen, M. K., Erikstrup, C., Hauge, E. M., Troldborg, A. (2021). Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis. Rheumatol. Int., 41 (11), 1925–1931. http://pubmed.gov. DOI: 10.1007/s00296-021-04972-7 (accessed 31.07.2022).
- Cherian, S., Paul, A., Ahmed, S., Alias, B., Manoj, M., Santhosh, A. K., Varghese, D. R., Krishnan, N., Shenoy, P. (2021). Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey. Rheumatol. Int., 41 (8), 1441–1445.
- Curtis, J. R., Johnson, S. R., Anthony, D. D., Arasaratnam, R. J., Baden, L. R., Bass, A. R., Calabrese, C., Gravallese, E. M., Harpaz, R., Kroger, A., et al. (2021). American College of Rheumatology Guidance for COVID-19 Vaccination in Patients with Rheumatic and Musculoskeletal Diseases: Version 3. Arthritis Rheumatol., 73 (10), e60–e75. http://pubmed.gov. DOI: 10.1002/art.41928 (accessed 01.08.2022).
- Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., et al; ISARIC4C investigators. (2020). Features of 20?133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. BMJ, 22, 369:m1985. http://pubmed.gov. DOI: 10.1136/bmj.m1985 (accessed 31.07.2022).
- Esquivel-Valerio, J. A., Skinner-Taylor, C. M., Moreno-Arquieta, I. A., Cardenas-de la Garza, J. A., Garcia-Arellano, G., Gonzalez-Garcia, P. L., Almaraz-Juarez, F. D. R., Galarza-Delgado, D. A. (2021). Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: A cross-sectional study. Rheumatol. Int., 41 (12), 2105–2108.
- Felten, R., Dubois, M., Ugarte-Gil, M. F., Chaudier, A., Kawka, L., Bergier, H., Costecalde, C., Pijnenburg, L., Fort, J., Chatelus, E., et al. (2021). Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases. Lancet Rheumatol., 3 (4), e243–e245. http://pubmed.gov. DOI: 10.1016/S2665-9913(21)00039-4 (accessed 31.07.2022).
- Furer, V., Eviatar, T., Zisman, D., Peleg, H., Paran, D., Levartovsky, D., Zisapel, M., Elalouf, O., Kaufman, I., Meidan, R., et al. (2021). Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis., 80, 1330–1338.
- Furer, V., Rondaan, C., Agmon-Levin, N., van Assen, S., Bijl, M., Kapetanovic, M. C., de Thurah, A., Mueller-Ladner, U., Paran, D., Schreiber, K., et al. (2021). Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases. RMD Open, 7 (1), e001594. http://pubmed.gov. DOI: 10.1136/rmdopen-2021-001594.2021 (accessed 31.07.2022).
- Han, X., Xu, P., Ye, Q. (2021). Analysis of COVID-19 vaccines: Types, thoughts, and application. J. Clin. Lab. Anal., 35 (9), e23937. http://pubmed.gov. DOI: 10.1002/jcla.23937 (accessed 31.07.2022).
- Kyriakidis, N. C., López-Cortés, A., González, E. V., Grimaldos, A. B., Prado, E. O. (2021). SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines., 6 (1), 28. http://pubmed.gov. DOI: 10.1038/s41541-021-00292-w (accessed 31.07.2022).
- Landewé, R. B. M., Kroon, F. P. B., Alunno, A., Najm, A., Bijlsma, J. W., Burmester, G. R., Caporali, R., Combe, B., Conway, R., Curtis, J. R., et al. (2022). EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Ann. Rheum. Dis., annrheumdis-2021-222006. http://pubmed.gov. DOI: 10.1136/annrheumdis-2021-222006 (accessed 31.07.2022).
- Machado, P. M., Lawson-Tovey, S., Strangfeld, A., Mateus, E. F., Hyrich, K. L., Gossec, L., Carmona, L., Rodrigues, A., Raffeiner, B., Duarte, C., et al. (2022). Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: Results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann. Rheum. Dis., 81 (5), 695–709.
- Sattui, S. E., Liew, J. W., Kennedy, K., Sirotich, E., Putman, M., Moni, T. T., Akpabio, A, Alpízar-Rodríguez, D., Berenbaum, F., Bulina, I., et al. (2021). Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open, 7 (3), e001814. http://pubmed.gov. DOI: 10.1136/rmdopen-2021-001814 (accessed 31.07.2022).
- Strangfeld, A., Schäfer, M., Gianfrancesco, M. A., Lawson-Tovey, S., Liew, J. W., Ljung, L., Mateus, E. F., Richez, C., Santos, M. J., Schmajuk, G., et al. (2021). COVID-19 Global Rheumatology Alliance. Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann. Rheum. Dis., 80 (7), 930–942.
- Williamson, E. J., Walker, A. J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C. E., Curtis, H. J., Mehrkar, A., Evans, D., Inglesby, P., et al. (2020). Factors associated with COVID-19-related death using OpenSAFELY. Nature, 584 (7821), 430-436.